We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
References
1
Seeley, E., Chimonas, S., and Kesselheim, A.S., “Can Outcomes-Based Pharmaceutical Contracts Reduce Drug Prices in the US?: A Mixed Methods Assessment, Journal of Law, Medicine & Ethics46, no. 4 (2018): 952–963.Google Scholar
2
Duhig, A.M., Saha, S., Smith, S., Kaufman, S., and Hughes, J., “The Current Status of Outcomes-Based Contracting for Manufacturers and Payers: An AMCP Membership Survey,”Journal of Managed Care & Specialty Pharmacy24, no 5 (2018): 410–415; Duke Robert J. Margolis MD Center for Health Policy, Center for Health Policy, Overcoming Legal and Regulatory Hurdles to Value-Based Payment Arrangements for Medical Products, December 2017.CrossRefGoogle Scholar
Dubois, R., Sherman, M., and Spurr, R., “More than Meets the Eye — Value-Based Contracts are More Prevalent than We Think,” paper presented at: AMCP Managed Care & Specialty Pharmacy Annual Meeting 2018, April 25, 2018, Boston, MA.Google Scholar
Nazareth, T., Ko, J.J., Sasane, R., et al., “Outcomes-Based Contracting Experience: Research Findings from U.S. and European Stakeholders, Journal of Managed Care & Specialty Pharmacy23, no. 10 (2017):1018–1026.Google ScholarPubMed